Keywords: Merck KGaA, cladribine, FDA approval delay

US FDA delays Merck KGaA’s filing on MS drug cladribine

Article | 01 December 2009

Print This

In a move that will delay the approval of German drug major Merck KGaA’s multiple sclerosis drug cladribine, the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in